The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice

Physiology and Behavior

Volumn 149, Issue , 2015, Pages 262-268

  Sørensen, Gunnar ^a   Reddy, India A ^b   Weikop, Pia ^a   Graham, Devon L ^c   Stanwood, Gregg D ^c   Wortwein, Gitta ^a   Galli, Aurelio ^b   Fink Jensen, Anders ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c FLORIDA STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Addiction; C Fos; Cocaine; Dopamine; Exendin 4; GLP 1; Self administration

Indexed keywords

COCAINE; DOPAMINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; EXENDIN 4; ANTIDIABETIC AGENT; BENZAZEPINE DERIVATIVE; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE UPTAKE INHIBITOR; PEPTIDE; PROTEIN C FOS; SK&F 82958; VENOM;

ANIMAL EXPERIMENT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DRUG SELF ADMINISTRATION; FOOD INTAKE; HOMEOSTASIS; LOCOMOTION; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEUS ACCUMBENS; ONCOGENE C FOS; PRIORITY JOURNAL; VENTRAL TEGMENTUM; ANALYSIS OF VARIANCE; ANIMAL; CHEMICALLY INDUCED; CORPUS STRIATUM; DOSE RESPONSE; DRUG EFFECTS; EXPLORATORY BEHAVIOR; GENE EXPRESSION REGULATION; GENETICS; HYPERKINESIA; METABOLISM; MICRODIALYSIS; MOTOR ACTIVITY; TIME FACTOR;

ANALYSIS OF VARIANCE; ANIMALS; BENZAZEPINES; COCAINE; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; GENE EXPRESSION REGULATION; HYPERKINESIS; HYPOGLYCEMIC AGENTS; MALE; MICE; MICRODIALYSIS; MOTOR ACTIVITY; PEPTIDES; PROTO-ONCOGENE PROTEINS C-FOS; SELF ADMINISTRATION; TIME FACTORS; VENOMS;

EID: 84934965796     PISSN: 00319384     EISSN: 1873507X     Source Type: Journal    
DOI: 10.1016/j.physbeh.2015.06.013     Document Type: Article

References (30)

1. Koob G.F. Drugs of abuse - anatomy, pharmacology and function of reward pathways. Trends Pharmacol. Sci. 1992, 13:177-184.
2. Koob G.F., Sanna P.P., Bloom F.E. Neuroscience of addiction. Neuron 1998, 21:467-476.
3. Novak U., Wilks A., Buell G., McEwen S. Identical mRNA for preproglucagon in pancreas and gut. Eur. J. Biochem. 1987, 164:553-558.
4. Orskov C., Wettergren A., Holst J.J. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand. J. Gastroenterol. 1996, 31:665-670.
5. Göke R., Larsen P.J., Mikkelsen J.D., Sheikh S.P. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur. J. Neurosci. 1995, 7:2294-2300.
6. Merchenthaler I., Lane M., Shrughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J. Comp. Neurol. 1999, 403:261-280.
7. Alhadeff A.L., Rupprecht L.E., Hayes M.R. GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology 2012, 153:647-658.
8. Holst J.J., Deacon C.F., Vilsbøl T., Krarup T., Madsbad S. Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends Mol. Med. 2008, 14:161-168.
9. Tang-Christensen M., Larsen P.L., Göke R., Fink-Jensen A., Jessup D.S., Møller M., et al. Central administration of GLP-1 (7-36) amide inhibits food and water intake in rats. J. Am. Physiol. 1996, 271:R848-R856.
10. Turton M.D., O'Shea D., Gunn I., Beak S.A., Edwards C.M.B., Meeran K., et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996, 379:69-72.
11. Vilsbøll T., Christensen M., Junker A.E., Knop F.K., Gluud L.L. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012, 344:d7771.
12. Kastin A.J., Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int. J. Obes. 2003, 27:313-318.
13. Kanoski S.E., Fortin S.M., Arnold M., Grill H.J., Hayes M.R. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology 2011, 152:3103-3112.
14. Dickson S.L., Shirazi R.H., Hansson C., Bergquist F., Nissbrandt H., Skibicka K.P. The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors. J. Neurosci. 2012, 32:4812-4820.
15. Reddy I.A., Stanwood G.D., Galli A. Moving beyond energy homeostasis: new roles for glucagon-like peptide-1 in food and drug reward. Neurochem. Int. 2013, 73:49-55.
16. Erreger K., Davis A.R., Poe A.M., Greig N.H., Stanwood G.D., Galli A. Exendin-4 decreases amphetamine-induced locomotor activity. Physiol. Behav. 2012, 106:574-578.
17. Graham D.L., Erreger K., Galli A., Stanwood G.D. GLP-1 analog attenuates cocaine reward. Mol. Psychiatry 2012, 18(9):961-962.
18. Egecioglu E., Steensland P., Freriksson I., Feltmann K., Engel J.A., Jerlhag E. The glucagon-like peptide 1 analogue exendin-4 attenuates alcohol mediated behaviors in rodents. Psychoneuroendocrinology 2013, 38(8):1259-1270.
19. Sørensen G., Jensen M., Weikop P., Dencker D., Christiansen S.H., Løland C.J., et al. Neuropeptide Y Y5 receptor antagonism attenuates addiction-related effects of cocaine in mice. Psychopharmacology 2012, 222:565-577.
20. Schmidt L.S., Thomsen M., Weikop P., Dencker D., Wess J., Woldbye D.P.D., et al. Increased cocaine self-administration in M4 muscarinic acetylcholine receptor knockout mice. Psychopharmacology 2011, 216:367-378.
21. Paxinos G., Franklin K.J.B. The Mouse Brain in Stereotaxic Coordinates 2001, Academic, New York.
22. Weikop P., Egestad C., Kehr J. Application of triple-probe microdialysis for fast pharmacokinetic/pharmacodynamic evaluation of dopaminergic activity of drug candidates in the rat brain. J. Neurosci. Methods 2004, 140:59-65.
23. Shirazi R.S., Dickson S.L., Skibicka K.P. Gut peptide GLP-1 and its analogue, exendin-4, decrease alcohol intake and reward. PLoS One 2013, 8. e61965.
24. Mello N.S., Negus S.S. Preclinical evaluation of pharmacotherapies for treat-ment of cocaine and opioid abuse using drug self-administration procedures. Neuropsychopharmacology 1996, 14:375-424.
25. Wise R.A. Roles for nigrostriatal - not just mesocorticolimbic - dopamine in reward and addiction. Trends Neurosci. 2009, 32:517-524.
26. Egecioglu E., Engel J.A., Jerlhag E. The glucagon-like peptide 1 analogue, exendin-4, attenuates the rewarding properties of psychostimulant drugs in mice. PLoS One 2013, 8. e69010.
27. Dossat A.M., Lilly N., Kay K., Williams D.J. Glucagon-like peptide 1 receptors in nucleus accumbens affect food intake. J. Neurosci. 2011, 31:14453-14457.
28. Groenewegen H.J., Wright C.I., Beijer A.V.J., Voorn P. Convergence and segregation of ventral striatal inputs and outputs. Ann. N. Y. Acad. Sci. 1999, 877:49-63.
29. Le Foll B., Gallo A., Le Strat Y., Lu L., Gorwood P. Genetics of dopamine receptors and drug addiction: a comprehensive review. Behav. Pharmacol. 2009, 20:1-17.
30. Nestler E.J. Molecular neurobiology of addiction. Am. J. Addict. 2001, 10:201-217.